Clinical Impact of Dual Time Point <sup>18</sup>F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Fusion Imaging in Pancreatic Cancer
We examined the value of preoperative dual time point (DTP) <sup>18</sup>F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (FDG PET/CT) as a predictor of early recurrence or the outcomes in patients with pancreatic cancer. Standardized uptake values (SU...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-07-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/15/3688 |
| _version_ | 1797414478262829056 |
|---|---|
| author | Takahiro Einama Yoji Yamagishi Yasuhiro Takihata Fukumi Konno Kazuki Kobayashi Naoto Yonamine Ibuki Fujinuma Takazumi Tsunenari Keita Kouzu Akiko Nakazawa Toshimitsu Iwasaki Eiji Shinto Jiro Ishida Hideki Ueno Yoji Kishi |
| author_facet | Takahiro Einama Yoji Yamagishi Yasuhiro Takihata Fukumi Konno Kazuki Kobayashi Naoto Yonamine Ibuki Fujinuma Takazumi Tsunenari Keita Kouzu Akiko Nakazawa Toshimitsu Iwasaki Eiji Shinto Jiro Ishida Hideki Ueno Yoji Kishi |
| author_sort | Takahiro Einama |
| collection | DOAJ |
| description | We examined the value of preoperative dual time point (DTP) <sup>18</sup>F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (FDG PET/CT) as a predictor of early recurrence or the outcomes in patients with pancreatic cancer. Standardized uptake values (SUVs) in DTP FDG PET/CT were performed as preoperative staging. SUVmax1 and SUVmax2 were obtained in 60 min and 120 min, respectively. ΔSUVmax% was defined as (SUVmax2 − SUVmax1)/SUVmax1 × 100. The optimal cut-off values for SUVmax parameters were selected based on tumor relapse within 1 year of surgery. Optimal cut-off values for SUVmax1 and ΔSUVmax% were 7.18 and 24.25, respectively. The combination of SUVmax1 and ΔSUVmax% showed higher specificity and sensitivity, and higher positive and negative predictive values for tumor relapse within 1 year than SUVmax1 alone. Relapse-free survival (RFS) was significantly worse in the subgroups of high SUVmax1 and high ΔSUVmax% (median 7.0 months) than in the other subgroups (<i>p</i> < 0.0001). The multivariate Cox analysis of RFS identified high SUVmax1 and high ΔSUVmax% as independent prognostic factors (<i>p</i> = 0.0060). DTP FDG PET/CT may effectively predict relapse in patients with pancreatic cancer. The combination of SUVmax1 and ΔSUVmax% identified early recurrent patient groups more precisely than SUVmax1 alone. |
| first_indexed | 2024-03-09T05:33:41Z |
| format | Article |
| id | doaj.art-c7cf0e63692f448ea13d7973a6e8aff8 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T05:33:41Z |
| publishDate | 2022-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-c7cf0e63692f448ea13d7973a6e8aff82023-12-03T12:30:54ZengMDPI AGCancers2072-66942022-07-011415368810.3390/cancers14153688Clinical Impact of Dual Time Point <sup>18</sup>F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Fusion Imaging in Pancreatic CancerTakahiro Einama0Yoji Yamagishi1Yasuhiro Takihata2Fukumi Konno3Kazuki Kobayashi4Naoto Yonamine5Ibuki Fujinuma6Takazumi Tsunenari7Keita Kouzu8Akiko Nakazawa9Toshimitsu Iwasaki10Eiji Shinto11Jiro Ishida12Hideki Ueno13Yoji Kishi14Department of Surgery, National Defense Medical College, Saitama 359-8513, JapanDepartment of Surgery, National Defense Medical College, Saitama 359-8513, JapanDepartment of Surgery, National Defense Medical College, Saitama 359-8513, JapanDepartment of Surgery, National Defense Medical College, Saitama 359-8513, JapanDepartment of Surgery, National Defense Medical College, Saitama 359-8513, JapanDepartment of Surgery, National Defense Medical College, Saitama 359-8513, JapanDepartment of Surgery, National Defense Medical College, Saitama 359-8513, JapanDepartment of Surgery, National Defense Medical College, Saitama 359-8513, JapanDepartment of Surgery, National Defense Medical College, Saitama 359-8513, JapanDepartment of Surgery, National Defense Medical College, Saitama 359-8513, JapanDepartment of Surgery, National Defense Medical College, Saitama 359-8513, JapanDepartment of Surgery, National Defense Medical College, Saitama 359-8513, JapanTokorozawa PET Diagnostic Imaging Clinic, Saitama 359-1124, JapanDepartment of Surgery, National Defense Medical College, Saitama 359-8513, JapanDepartment of Surgery, National Defense Medical College, Saitama 359-8513, JapanWe examined the value of preoperative dual time point (DTP) <sup>18</sup>F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (FDG PET/CT) as a predictor of early recurrence or the outcomes in patients with pancreatic cancer. Standardized uptake values (SUVs) in DTP FDG PET/CT were performed as preoperative staging. SUVmax1 and SUVmax2 were obtained in 60 min and 120 min, respectively. ΔSUVmax% was defined as (SUVmax2 − SUVmax1)/SUVmax1 × 100. The optimal cut-off values for SUVmax parameters were selected based on tumor relapse within 1 year of surgery. Optimal cut-off values for SUVmax1 and ΔSUVmax% were 7.18 and 24.25, respectively. The combination of SUVmax1 and ΔSUVmax% showed higher specificity and sensitivity, and higher positive and negative predictive values for tumor relapse within 1 year than SUVmax1 alone. Relapse-free survival (RFS) was significantly worse in the subgroups of high SUVmax1 and high ΔSUVmax% (median 7.0 months) than in the other subgroups (<i>p</i> < 0.0001). The multivariate Cox analysis of RFS identified high SUVmax1 and high ΔSUVmax% as independent prognostic factors (<i>p</i> = 0.0060). DTP FDG PET/CT may effectively predict relapse in patients with pancreatic cancer. The combination of SUVmax1 and ΔSUVmax% identified early recurrent patient groups more precisely than SUVmax1 alone.https://www.mdpi.com/2072-6694/14/15/3688pancreatic cancerdual time point PET/CTSUVmax1SUVmax2ΔSUVmax% |
| spellingShingle | Takahiro Einama Yoji Yamagishi Yasuhiro Takihata Fukumi Konno Kazuki Kobayashi Naoto Yonamine Ibuki Fujinuma Takazumi Tsunenari Keita Kouzu Akiko Nakazawa Toshimitsu Iwasaki Eiji Shinto Jiro Ishida Hideki Ueno Yoji Kishi Clinical Impact of Dual Time Point <sup>18</sup>F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Fusion Imaging in Pancreatic Cancer Cancers pancreatic cancer dual time point PET/CT SUVmax1 SUVmax2 ΔSUVmax% |
| title | Clinical Impact of Dual Time Point <sup>18</sup>F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Fusion Imaging in Pancreatic Cancer |
| title_full | Clinical Impact of Dual Time Point <sup>18</sup>F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Fusion Imaging in Pancreatic Cancer |
| title_fullStr | Clinical Impact of Dual Time Point <sup>18</sup>F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Fusion Imaging in Pancreatic Cancer |
| title_full_unstemmed | Clinical Impact of Dual Time Point <sup>18</sup>F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Fusion Imaging in Pancreatic Cancer |
| title_short | Clinical Impact of Dual Time Point <sup>18</sup>F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Fusion Imaging in Pancreatic Cancer |
| title_sort | clinical impact of dual time point sup 18 sup f fluorodeoxyglucose positron emission tomography computed tomography fusion imaging in pancreatic cancer |
| topic | pancreatic cancer dual time point PET/CT SUVmax1 SUVmax2 ΔSUVmax% |
| url | https://www.mdpi.com/2072-6694/14/15/3688 |
| work_keys_str_mv | AT takahiroeinama clinicalimpactofdualtimepointsup18supffluorodeoxyglucosepositronemissiontomographycomputedtomographyfusionimaginginpancreaticcancer AT yojiyamagishi clinicalimpactofdualtimepointsup18supffluorodeoxyglucosepositronemissiontomographycomputedtomographyfusionimaginginpancreaticcancer AT yasuhirotakihata clinicalimpactofdualtimepointsup18supffluorodeoxyglucosepositronemissiontomographycomputedtomographyfusionimaginginpancreaticcancer AT fukumikonno clinicalimpactofdualtimepointsup18supffluorodeoxyglucosepositronemissiontomographycomputedtomographyfusionimaginginpancreaticcancer AT kazukikobayashi clinicalimpactofdualtimepointsup18supffluorodeoxyglucosepositronemissiontomographycomputedtomographyfusionimaginginpancreaticcancer AT naotoyonamine clinicalimpactofdualtimepointsup18supffluorodeoxyglucosepositronemissiontomographycomputedtomographyfusionimaginginpancreaticcancer AT ibukifujinuma clinicalimpactofdualtimepointsup18supffluorodeoxyglucosepositronemissiontomographycomputedtomographyfusionimaginginpancreaticcancer AT takazumitsunenari clinicalimpactofdualtimepointsup18supffluorodeoxyglucosepositronemissiontomographycomputedtomographyfusionimaginginpancreaticcancer AT keitakouzu clinicalimpactofdualtimepointsup18supffluorodeoxyglucosepositronemissiontomographycomputedtomographyfusionimaginginpancreaticcancer AT akikonakazawa clinicalimpactofdualtimepointsup18supffluorodeoxyglucosepositronemissiontomographycomputedtomographyfusionimaginginpancreaticcancer AT toshimitsuiwasaki clinicalimpactofdualtimepointsup18supffluorodeoxyglucosepositronemissiontomographycomputedtomographyfusionimaginginpancreaticcancer AT eijishinto clinicalimpactofdualtimepointsup18supffluorodeoxyglucosepositronemissiontomographycomputedtomographyfusionimaginginpancreaticcancer AT jiroishida clinicalimpactofdualtimepointsup18supffluorodeoxyglucosepositronemissiontomographycomputedtomographyfusionimaginginpancreaticcancer AT hidekiueno clinicalimpactofdualtimepointsup18supffluorodeoxyglucosepositronemissiontomographycomputedtomographyfusionimaginginpancreaticcancer AT yojikishi clinicalimpactofdualtimepointsup18supffluorodeoxyglucosepositronemissiontomographycomputedtomographyfusionimaginginpancreaticcancer |